Cartesian Therapeutics, Inc.
RNACNASDAQHealthcare● Active
$5.86
+$0.02(+0.34%)
Market Cap$172175590
P/E Ratio—
52W High$15.57
52W Low$5.6
Cartesian Therapeutics, Inc. (RNAC) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · RNAC · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $2.80M | $38.91M | $26.00M | $110.78M | $85.08M |
| Cost of Revenue | $0.00M | $0.00M | $0.00M | $2.04M | $0.00M |
| Gross Profit | $2.80M | $38.91M | $26.00M | $108.74M | $85.08M |
| Gross Margin %(computed) | 100.00% | 100.00% | 100.00% | 98.16% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $58.03M | $45.10M | $71.26M | $72.38M | $68.74M |
| G&A Expenses | $31.47M | $30.13M | $40.45M | $23.86M | $20.94M |
| Total Operating Expenses | $89.50M | $82.81M | $112.42M | $94.20M | $89.67M |
| Operating Income | ($86.70M) | ($43.90M) | ($86.42M) | $14.54M | ($4.60M) |
| Operating Margin %(computed) | — | -112.81% | -332.32% | 13.12% | -5.40% |
| Interest Income | $6.58M | $7.39M | $4.96M | $0.00M | $0.00M |
| Interest Expense | $0.00M | $0.00M | $2.83M | $3.03M | $2.84M |
| Income Before Tax | ($139.50M) | ($77.14M) | ($238.71M) | $34.77M | ($9.72M) |
| Income Tax Expense | ($9.19M) | $0.29M | ($19.00M) | ($0.61M) | $15.97M |
| Net Income | ($130.30M) | ($77.42M) | ($219.71M) | $35.38M | ($25.69M) |
| Net Margin %(computed) | — | -198.97% | -844.91% | 31.94% | -30.19% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.02 | $-2.99 | $-49.76 | $7.33 | $-6.74 |
| Wtd Avg Shares | 25.97M | 25.91M | 5.17M | 4.02M | 3.18M |
| EBITDA | ($86.70M) | ($75.99M) | ($235.03M) | $39.84M | ($5.16M) |
| EBITDA Margin %(computed) | — | -195.27% | -903.84% | 35.96% | -6.06% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Cartesian Therapeutics, Inc. data
About Cartesian Therapeutics, Inc. (RNAC) Income Statement
Cartesian Therapeutics, Inc. (RNAC) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, RNAC reported revenue of $0.00B, gross profit of $0.00B (gross margin 100.00%), and net income of ($0.13B) — a net profit margin of -4658.63%.
Frequently asked questions
RNAC · 4 questionsCartesian Therapeutics, Inc. (RNAC) reported revenue of $0.00B for 2025, down 92.8% year-over-year.
RNAC revenueRNAC salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08